This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

GBR 900

Glenmark Pharmaceuticals Limited

Drug Names(s): huMNAC13, BXL1H5

Description: BXL1H5 is a humanized monoclonal antibody (antagonist) directed against TrkA, a receptor for nerve growth factor (NGF) involved in pain hypersensitivity associated with tissue injury and inflammation. TrkA is found on primary afferent nociceptor nerves and mast cells (where it causes release of pro-pain molecules, including NGF).

Deal Structure: Bioxell and Lay Line Genomics
On December 16, 2005, Bioxell entered into an exclusive worldwide license agreement with Lay Line Genomics (LLG) to develop MNAC13 for the treatment of chronic pain. According to the agreement, BioXell will take MNAC13 through development and potential commercialisation, in exchange for a EUR 0.3 million up-frontpayment and milestones and royalties to LLG, payable upon achievement of various clinical or regulatory events. Future milestones are payable upon achievement of various clinical or regulatory events (first patient dosing in Phase I, II and II clinical trials, regulatory filing and approval).

On February 16, 2010, BioXell announced that it has terminated its efforts to divest BXL1H5 prior to the settlement of the public tender offer by Cosmo Pharmaceuticals for the shares of BioXell. BioXell and LLG will now mutually terminate the exclusive license agreement and BioXell will return all rights to the BXL1H5 technology to...See full deal structure in Biomedtracker

Partners: Lay Line Genomics S.p.A.

GBR 900 News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug